Measles virus defective interfering RNAs are generated frequently and early in the absence of C protein and can be destabilized by adenosine deaminase acting on RNA-1-like hypermutations

Journal of Virology

Volumn 89, Issue 15, 2015, Pages 7735-7747

  Pfaller, Christian K ^a   Mastorakos, George M ^a,b   Matchett, William E ^a,b   Ma, Xiao ^a,b   Samuel, Charles E ^c   Cattaneo, Roberto ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE DEAMINASE ACTING ON RNA 1; DEFECTIVE INTERFERING RNA; PROTEIN C; PROTEIN KINASE R; UNCLASSIFIED DRUG; VIRUS RNA; ADAR1 PROTEIN, HUMAN; C PROTEIN, MEASLES VIRUS; RNA BINDING PROTEIN; SMALL INTERFERING RNA; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GEL ELECTROPHORESIS; HELA CELL LINE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MEASLES VIRUS; MOLECULAR CLONING; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VERO CELL LINE; VIRION; WILD TYPE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MEASLES; METABOLISM; MUTATION; PROTEIN STABILITY; RNA EDITING; VIROLOGY;

MEASLES VIRUS; RNA VIRUSES;

ADENOSINE DEAMINASE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MEASLES; MEASLES VIRUS; MUTATION; PROTEIN STABILITY; RNA EDITING; RNA, SMALL INTERFERING; RNA, VIRAL; RNA-BINDING PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84937683546     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01017-15     Document Type: Article

References (70)

1. Rima BK, Duprex WP. 2009. The measles virus replication cycle. Curr Top Microbiol Immunol 329:77-102. http://dx.doi.org/10.1007/978-3-540-70523-9_5.
2. Lamb RA, Parks GD. 2013. Paramyxoviridae, p 957-995. In Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed), Fields virology, 6th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Griffin DE. 2013. Measles virus, p 1042-1069. In Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed), Fields virology, 6th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
4. Longhi S. 2009. Nucleocapsid structure and function. Curr Top Microbiol Immunol 329:103-128. http://dx.doi.org/10.1007/978-3-540-70523-9_6.
5. Schrag SJ, Rota PA, Bellini WJ. 1999. Spontaneous mutation rate of measles virus: direct estimation based on mutations conferring monoclonal antibody resistance. J Virol 73:51-54.
6. Domingo E, Sheldon J, Perales C. 2012. Viral quasispecies evolution. Microbiol Mol Biol Rev 76:159-216. http://dx.doi.org/10.1128/MMBR.05023-11.
7. Domingo E, Holland JJ. 1997. RNA virus mutations and fitness for survival. Annu Rev Microbiol 51:151-178. http://dx.doi.org/10.1146/annurev.micro.51.1.151.
8. Moya A, Elena SF, Bracho A, Miralles R, Barrio E. 2000. The evolution of RNA viruses: a population genetics view. Proc Natl Acad Sci USA 97:6967-6973. http://dx.doi.org/10.1073/pnas.97.13.6967.
9. Kolakofsky D. 1976. Isolation and characterization of Sendai virus DIRNAs. Cell 8:547-555. http://dx.doi.org/10.1016/0092-8674(76)90223-3.
10. Calain P, Roux L. 1993. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J Virol 67:4822-4830.
11. Holland JJ, Kennedy SIT, Semler BL, Jones CL, Roux L, Grabau EA. 1980. Defective interfering RNA viruses and the host-cell response, p 137-192. In Fraenkel-Conrat H, Wagner RR (ed), Comprehensive virology, vol.16. Plenum Press, New York, NY.
12. Baum A, Sachidanandam R, Garcia-Sastre A. 2010. Preference of RIG-I for short viralRNAmolecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci USA 107:16303-16308. http://dx.doi.org/10.1073/pnas.1005077107.
13. Runge S, Sparrer KM, Lassig C, Hembach K, Baum A, Garcia-Sastre A, Soding J, Conzelmann KK, Hopfner KP. 2014. In vivo ligands of MDA5 and RIG-I in measles virus-infected cells. PLoS Pathog 10:e1004081. http://dx.doi.org/10.1371/journal.ppat.1004081.
14. Pfaller CK, Radeke MJ, Cattaneo R, Samuel CE. 2014. Measles virus C protein impairs production of defective copyback double-stranded viral RNA and activation of protein kinase R. J Virol 88:456-468. http://dx.doi.org/10.1128/JVI.02572-13.
15. Huang AS. 1973. Defective interfering viruses. Annu Rev Microbiol 27: 101-117. http://dx.doi.org/10.1146/annurev.mi.27.100173.000533.
16. Devaux P, von Messling V, Songsungthong W, Springfeld C, Cattaneo R. 2007. Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology 360:72-83. http://dx.doi.org/10.1016/j.virol.2006.09.049.
17. Takeda M, Takeuchi K, Miyajima N, Kobune F, Ami Y, Nagata N, Suzaki Y, Nagai Y, Tashiro M. 2000. Recovery of pathogenic measles virus from cloned cDNA. J Virol 74:6643-6647. http://dx.doi.org/10.1128/JVI.74.14.6643-6647.2000.
18. Marcus PI, Gaccione C. 1989. Interferon induction by viruses. XIX. Vesicular stomatitis virus-New Jersey: high multiplicity passages generate interferon-inducing, defective-interfering particles. Virology 171: 630-633.
19. O'Hara PJ, Nichol ST, Horodyski FM, Holland JJ. 1984. Vesicular stomatitis virus defective interfering particles can contain extensive genomic sequence rearrangements and base substitutions. Cell 36:915-924. http://dx.doi.org/10.1016/0092-8674(84)90041-2.
20. Huang AS, Baltimore D. 1970. Defective viral particles and viral disease processes. Nature 226:325-327. http://dx.doi.org/10.1038/226325a0.
21. Eggington JM, Greene T, Bass BL. 2011. Predicting sites of ADAR editing in double-stranded RNA. Nat Commun 2:319. http://dx.doi.org/10.1038/ncomms1324.
22. Wulff BE, Sakurai M, Nishikura K. 2011. Elucidating the inosinome: global approaches to adenosine-to-inosine RNA editing. Nat Rev Genet 12:81-85. http://dx.doi.org/10.1038/nrg2915.
23. Lehmann KA, Bass BL. 2000. Double-stranded RNA adenosine deaminases ADAR1 and ADAR2 have overlapping specificities. Biochemistry 39:12875-12884. http://dx.doi.org/10.1021/bi001383g.
24. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, Yanagi Y. 2001. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol 75:4399-4401. http://dx.doi.org/10.1128/JVI.75.9.4399-4401.2001.
25. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C, Christiansen G, Billeter MA. 1995. Rescue of measles viruses from cloned DNA. EMBO J 14:5773-5784.
26. Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, De Schouwer PJ, Lens D, Bartek J, Dyer MJ, Kruger AR, Catovsky D. 1997. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 11:64-72.
27. del Valle JR, Devaux P, Hodge G, Wegner NJ, McChesney MB, Cattaneo R. 2007. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 81:10597-10605. http://dx.doi.org/10.1128/JVI.00923-07.
28. Taylor MP, Kobiler O, Enquist LW. 2012. Alphaherpesvirus axon-to-cell spread involves limited virion transmission. Proc Natl Acad Sci USA 109:17046-17051. http://dx.doi.org/10.1073/pnas.1212926109.
29. Toth AM, Devaux P, Cattaneo R, Samuel CE. 2009. Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-deficient measles virus. J Virol 83:961-968. http://dx.doi.org/10.1128/JVI.01669-08.
30. Cathomen T, Naim HY, Cattaneo R. 1998. Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol 72:1224-1234.
31. Schonborn J, Oberstrass J, Breyel E, Tittgen J, Schumacher J, Lukacs N. 1991. Monoclonal antibodies to double-stranded RNA as probes of RNA structure in crude nucleic acid extracts. Nucleic Acids Res 19:2993-3000. http://dx.doi.org/10.1093/nar/19.11.2993.
32. Rager M, Vongpunsawad S, Duprex WP, Cattaneo R. 2002. Polyploid measles virus with hexameric genome length. EMBO J 21:2364-2372. http://dx.doi.org/10.1093/emboj/21.10.2364.
33. Cattaneo R. 1994. Biased (A → I) hypermutation of animal RNA virus genomes. Curr Opin Genet Dev 4:895-900. http://dx.doi.org/10.1016/0959-437X(94)90076-0.
34. Cattaneo R, Schmid A, Eschle D, Baczko K, ter Meulen V, Billeter MA. 1988. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell 55:255-265. http://dx.doi.org/10.1016/0092-8674(88)90048-7.
35. Kim U, Wang Y, Sanford T, Zeng Y, Nishikura K. 1994. Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci USA 91: 11457-11461. http://dx.doi.org/10.1073/pnas.91.24.11457.
36. Bass BL, Weintraub H. 1988. An unwinding activity that covalently modifies its double-strandedRNAsubstrate. Cell 55:1089-1098. http://dx.doi.org/10.1016/0092-8674(88)90253-X.
37. Cattaneo R, Rebmann G, Schmid A, Baczko K, ter Meulen V, Billeter MA. 1987. Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J 6:681-688.
38. Bankamp B, Wilson J, Bellini WJ, Rota PA. 2005. Identification of naturally occurring amino acid variations that affect the ability of the measles virus C protein to regulate genome replication and transcription. Virology 336:120-129. http://dx.doi.org/10.1016/j.virol.2005.03.009.
39. Sleeman K, Bankamp B, Hummel KB, Lo MK, Bellini WJ, Rota PA. 2008. The C, V and W proteins of Nipah virus inhibit minigenome replication. J Gen Virol 89:1300-1308. http://dx.doi.org/10.1099/vir.0.83582-0.
40. Curran J, Marq JB, Kolakofsky D. 1992. The Sendai virus nonstructural C proteins specifically inhibit viral mRNA synthesis. Virology 189:647-656. http://dx.doi.org/10.1016/0042-6822(92)90588-G.
41. Irie T, Nagata N, Yoshida T, Sakaguchi T. 2008. Paramyxovirus Sendai virus C proteins are essential for maintenance of negative-sense RNA genome in virus particles. Virology 374:495-505. http://dx.doi.org/10.1016/j.virol.2008.01.004.
42. Irie T, Okamoto I, Yoshida A, Nagai Y, Sakaguchi T. 2014. Sendai virus C proteins regulate viral genome and antigenome synthesis to dictate the negative genome polarity. J Virol 88:690-698. http://dx.doi.org/10.1128/JVI.02798-13.
43. Boonyaratanakornkit J, Bartlett E, Schomacker H, Surman S, Akira S, Bae YS, Collins P, Murphy B, Schmidt A. 2011. The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R. J Virol 85:1495-1506. http://dx.doi.org/10.1128/JVI.01297-10.
44. Takeuchi K, Komatsu T, Kitagawa Y, Sada K, Gotoh B. 2008. Sendai virus C protein plays a role in restricting PKR activation by limiting the generation of intracellular double-stranded RNA. J Virol 82:10102-10110. http://dx.doi.org/10.1128/JVI.00599-08.
45. Devaux P, Hodge G, McChesney MB, Cattaneo R. 2008. Attenuation of V-or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J Virol 82:5359-5367. http://dx.doi.org/10.1128/JVI.00169-08.
46. Mathieu C, Guillaume V, Volchkova VA, Pohl C, Jacquot F, Looi RY, Wong KT, Legras-Lachuer C, Volchkov VE, Lachuer J, Horvat B. 2012. Nonstructural Nipah virus C protein regulates both the early host proinflammatory response and viral virulence. J Virol 86:10766-10775. http://dx.doi.org/10.1128/JVI.01203-12.
47. Timm C, Akpinar F, Yin J. 2014. Quantitative characterization of defective virus emergence by deep sequencing. J Virol 88:2623-2632. http://dx.doi.org/10.1128/JVI.02675-13.
48. Re GG, Gupta KC, Kingsbury DW. 1983. Sequence of the 5' end of the Sendai virus genome and its variable representation in complementary form at the 3' ends of copy-back defective interfering RNA species: identification of the L gene terminus. Virology 130:390-396. http://dx.doi.org/10.1016/0042-6822(83)90093-4.
49. Re GG, Gupta KC, Kingsbury DW. 1983. Genomic and copy-back 3' termini in Sendai virus defective interfering RNA species. J Virol 45: 659-664.
50. Shivakoti R, Siwek M, Hauer D, Schultz KL, Griffin DE. 2013. Induction of dendritic cell production of type I and type III interferons by wild-type and vaccine strains of measles virus: role of defective interfering RNAs. J Virol 87:7816-7827. http://dx.doi.org/10.1128/JVI.00261-13.
51. Mercado-Lopez X, Cotter CR, Kim WK, Sun Y, Munoz L, Tapia K, Lopez CB. 2013. Highly immunostimulatory RNA derived from a Sendai virus defective viral genome. Vaccine 31:5713-5721. http://dx.doi.org/10.1016/j.vaccine.2013.09.040.
52. Pfaller CK, Li Z, George CX, Samuel CE. 2011. Protein kinase PKR and RNA adenosine deaminase ADAR1: new roles for old players as modulators of the interferon response. Curr Opin Immunol 23:573-582. http://dx.doi.org/10.1016/j.coi.2011.08.009.
53. Samuel CE. 2011. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 411:180-193. http://dx.doi.org/10.1016/j.virol.2010.12.004.
54. Li Z, Okonski KM, Samuel CE. 2012. Adenosine deaminase acting on RNA 1 (ADAR1) suppresses the induction of interferon by measles virus. J Virol 86:3787-3794. http://dx.doi.org/10.1128/JVI.06307-11.
55. Toth AM, Li Z, Cattaneo R, Samuel CE. 2009. RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR. J Biol Chem 284:29350-29356. http://dx.doi.org/10.1074/jbc.M109.045146.
56. Okonski KM, Samuel CE. 2013. Stress granule formation induced by measles virus is protein kinase PKR dependent and impaired by RNA adenosine deaminase ADAR1. J Virol 87:756-766. http://dx.doi.org/10.1128/JVI.02270-12.
57. John L, Samuel CE. 2014. Induction of stress granules by interferon and down-regulation by the cellular RNA adenosine deaminase ADAR1. Virology 454-455:299-310. http://dx.doi.org/10.1016/j.virol.2014.02.025.
58. George CX, John L, Samuel CE. 2014. An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1). J Interferon Cytokine Res 34:437-446. http://dx.doi.org/10.1089/jir.2014.0001.
59. Patterson JB, Samuel CE. 1995. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol 15:5376-5388.
60. Cattaneo R, Schmid A, Spielhofer P, Kaelin K, Baczko K, ter Meulen V, Pardowitz J, Flanagan S, Rima BK, Udem SA, Billeter MA. 1989. Mutated and hypermutated genes of persistent measles viruses which caused lethal human brain diseases. Virology 173:415-425. http://dx.doi.org/10.1016/0042-6822(89)90554-0.
61. Otani S, Ayata M, Takeuchi K, Takeda M, Shintaku H, Ogura H. 2014. Biased hypermutation occurred frequently in a gene inserted into the IC323 recombinant measles virus during its persistence in the brains of nude mice. Virology 462-463:91-97. http://dx.doi.org/10.1016/j.virol.2014.05.035.
62. van den Hoogen BG, van Boheemen S, de Rijck J, van Nieuwkoop S, Smith DJ, Laksono B, Gultyaev A, Osterhaus AD, Fouchier RA. 2014. Excessive production and extreme editing of human metapneumovirus defective interfering RNA is associated with type I IFN induction. J Gen Virol 95:1625-1633. http://dx.doi.org/10.1099/vir.0.066100-0.
63. Rima BK, Gatherer D, Young DF, Norsted H, Randall RE, Davison AJ. 2014. Stability of the parainfluenza virus 5 genome revealed by deep sequencing of strains isolated from different hosts and following passage in cell culture. J Virol 88:3826-3836. http://dx.doi.org/10.1128/JVI.03351-13.
64. Bellocq C, Mottet G, Roux L. 1990. Wide occurrence of measles virus subgenomic RNAs in attenuated live-virus vaccines. Biologicals 18:337-343. http://dx.doi.org/10.1016/1045-1056(90)90039-3.
65. Calain P, Roux L. 1988. Generation of measles virus defective interfering particles and their presence in a preparation of attenuated live-virus vaccine. J Virol 62:2859-2866.
66. Pfaller CK, Cattaneo R, Schnell MJ. 2015. Reverse genetics of Mononegavirales: how they work, new vaccines, and new cancer therapeutics. Virology 479-480C:331-344. http://dx.doi.org/10.1016/j.virol.2015.01.029.
67. Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ, Despres P, Tauber E, Jilma B, Tangy F. 2015. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, activecomparator, first-in-man trial. Lancet Infect Dis 15:519-527. http://dx.doi.org/10.1016/S1473-3099(15)70043-5.
68. Stebbings R, Fevrier M, Li B, Lorin C, Koutsoukos M, Mee E, Rose N, Hall J, Page M, Almond N, Voss G, Tangy F. 2012. Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS One 7:e50397. http://dx.doi.org/10.1371/journal.pone.0050397.
69. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG. 2009. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 20:1119-1132. http://dx.doi.org/10.1089/hum.2009.135.
70. Miest TS, Cattaneo R. 2014. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 12:23-34. http://dx.doi.org/10.1038/nrmicro3140.